| ID | 1137 |
| Name of the vaccine | NEISVAC-C |
| Microbe | Bacteria |
| Disease name | Meningococcal disease |
| Name of bacteria | Neisseria meningitidis |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | From 8 weeks |
| Description of the vaccine | Monovalent Meningococcal group C conjugate vaccine. |
| Name of the manufacturer | Pfizer |
| Name of the manufacturing country | New Zealand |
| Year of manufacture | 2008 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-negative diplococcus. |
| Efficacy | No protective efficacy studies conducted with NeisVac-C vaccine. |
| Vaccine formulation | Semi-opaque white to off-white suspension |
| Dosage | Infants 8 weeks to 11 months: Two doses 8 weeks apart. Booster at 12 months of age.
12 months and under 7 years: Single dose. Booster dose if still at risk 2-3 years later.
Greater than 7 years: Single dose. Booster dose if at risk 5 years later. |
| Mechanism of action | T-cell dependent response. |
| Route of administration | Intramuscular |
| Indications | Prevention of invasive disease caused by Neisseria meningitidis serogroup C. |
| Export | NA |
| Approval | NA |
| Adjuvant | Aluminium hydroxide hydrate |
| Repurposing | NA |
| Side effects of vaccine | In infants and children: Mild fever, decreased appetite, irritability, malaise.
In adults : Headache |
| Post vaccination | NA |
| Dose type | Both |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.immune.org.nz/vaccines/available-vaccines/neisvac-c |
| Other name | NA |
| Additional Links | NA
|